As per the agreement, CEOLIA and Activus will jointly conduct research and development to assess the feasibility of development of a novel oral formulation using Activus Pure Nano-particle Technology (APNT).
Sosei is a biopharmaceutical company anchored in Japan. It practises a reduced risk business model by acquiring a global reach, the company said.
CEOLIA is a specialty pharmaceutical company that focuses on development and commercialization of pharmaceutical products for the sensory organs ear, nose and throat.